Transgene and Nec report 100% three-year disease-free survival with TG4050
Transgene and Nec say TG4050 showed 100% three-year disease-free survival, with a Nature Communications peer-reviewed publication highlighting Phase 1 clinical and translational findings and durable neoantigen-specific T cell responses.
TG4050 as a single agent has the potential to prevent recurrence in head and neck cancerPeer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responsesTogether, the long-term clinical and translati…